arrow
T

Tammy Huang

regeneron
H指数:22
被引数:6,667

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo

基于全人源T细胞受体模拟抗体的CAR T细胞在体内表现出强大的抗肿瘤活性。

2025-03-260
PRE
A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Ra strengthens T cell-mediated anti-tumor therapies
2024-10-010
OAAI
REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
2023-12-010
PRE
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
2023-06-212
OAAI
A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy
2023-04-041
PRE
Blocking common ? chain cytokine signaling ameliorates T cell-mediated pathogenesis in disease models
2023-01-117
PRE
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

通过CD3亲和力调节产生具有细胞因子释放和生物分布的分化特征的T细胞重定向双特异性抗体

2021-07-1364
OAAI
Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine
2020-12-1823
PREAI
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies

一类增强CD3-bispecific抗体抗肿瘤活性的共刺激CD28-bispecific抗体

2020-01-0894
OAAI
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation

需要用IL-4Rα 抗体dupilumab双重阻断IL-4和IL-13,以广泛抑制2型炎症

2020-01-03269
OAAI
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
2019-12-264
OAAI
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
2019-06-19100
OAAI
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

开发治疗非人类灵长类动物晚期埃博拉病毒疾病的临床阶段人类单克隆抗体

2018-05-31144
OAAI
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
2017-05-02125
OAAI
Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes
2016-05-2735
OAAI
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection

在新型人源化mers-cov感染小鼠模型中针对Spike蛋白的完全人抗体的暴露前和暴露后功效

2015-06-29204
OAAI